Investigational drug · Phase 3
QLS31905
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumor, CLDN18.2-positive Advanced Biliary Tract Cancer, Gastric Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
7
Any phase or sponsor naming "QLS31905"
First trial start
2024
Jun 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLS31905", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- CLDN18.2-positive Advanced Biliary Tract Cancer
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "QLS31905" as an intervention, largest first.
- A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic CancerPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07079228 · 602 participants (planned) · Start Sep 8, 2025 · Primary completion Dec 2028
Drug: QLS31905; Nab-paclitaxel. and 4 more · For: Pancreatic Cancer
Sites: Beijing, China
- QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07716449 · 560 participants (planned) · Start Sep 24, 2026 · Primary completion Sep 2028
Drug: QLS31905; Sintilimab and 2 more · For: Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Beijing, China
- Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06446388 · 360 participants (planned) · Start Jun 30, 2024 · Primary completion Jun 30, 2026
Drug: QLS31905; Oxaliplatin and 5 more · For: Advanced Solid Tumor
Sites: Beijing, China
- Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07151872 · 120 participants (planned) · Start Sep 2025 · Primary completion Oct 2026
Drug: QLS31905 for Injection; Gemcitabine Hydrochloride for Injection and 4 more · For: CLDN18.2-positive Advanced Biliary Tract Cancer
- A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid TumorsStatus unknown
Qilu Pharmaceutical Co., Ltd.Industry
NCT06041035 · 115 participants (planned) · Start Oct 2023 · Primary completion Oct 2024
Drug: QLS31905; Nab paclitaxel and 4 more · For: Solid Tumor
Sites: Beijing, China
Qilu Pharmaceutical Co., Ltd.Industry
NCT05278832 · 104 participants (planned) · Start Oct 25, 2021 · Primary completion Dec 31, 2022
Drug: QLS31905 · For: Advanced Solid Tumors
Sites: Beijing, China
Qilu Pharmaceutical Co., Ltd.Industry
NCT06942767 · 100 participants (planned) · Start Jun 2025 · Primary completion Dec 2026
Drug: QLS31905 for Injection; QL2107 Injection and 2 more · For: Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.